MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
3.655
-0.015
-0.41%
Pre Market: 3.682 +0.027 +0.74% 08:31 11/09 EST
OPEN
3.650
PREV CLOSE
3.670
HIGH
3.750
LOW
3.620
VOLUME
72
TURNOVER
0
52 WEEK HIGH
5.45
52 WEEK LOW
3.500
MARKET CAP
724.08M
P/E (TTM)
4.666
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABUS last week (1026-1030)?
Weekly Report · 11/02 10:08
Healthcare stocks with strong revenue growth and attractive valuations
Seeking Alpha · 10/27 11:10
Weekly Report: what happened at ABUS last week (1019-1023)?
Weekly Report · 10/26 10:08
FDA Lifts Three-Year Freeze On Arbutus Biopharma's Hepatitis B Study
Benzinga · 10/22 14:25
Arbutus Biopharma's AB-101 Gets FDA Hold Lifted In Hepatitis B Program
NASDAQ · 10/22 14:12
FDA lifts clinical hold on Arbutus Biopharma AB-101 IND application
TipRanks · 10/22 11:40
Arbutus Biopharma Says FDA Lifts Clinical Hold On AB-101 IND, Company May Now Engage In Additional Clinical Development For AB-101 In US
Benzinga · 10/22 11:35
Weekly Report: what happened at ABUS last week (1012-1016)?
Weekly Report · 10/19 10:08
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.